Russ Hawkinson - 01 Feb 2022 Form 4 Insider Report for Silverback Therapeutics, Inc. (SPRY)

Role
Sr. Vice President of Finance
Signature
/s/ Jeffrey C. Pepe, Attorney-in-Fact
Issuer symbol
SPRY
Transactions as of
01 Feb 2022
Net transactions value
$0
Form type
4
Filing time
02 Feb 2022, 16:22:43 UTC
Previous filing
24 Feb 2022
Next filing
04 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Award $0 +7,500 +516% $0.000000 8,954 01 Feb 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (right to buy) Award $0 +45,000 $0.000000 45,000 01 Feb 2022 Common Stock 45,000 $4.85 Direct F3
transaction SPRY Stock Option (right to buy) Award $0 +28,500 $0.000000 28,500 01 Feb 2022 Common Stock 28,500 $4.85 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock.
F2 Includes 1,216 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2021.
F3 The shares subject to the option vest in equal monthly installments over the 48 months following February 1, 2022.
F4 25% of the shares subject to the option vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years.